Asahi Kasei Pharma has announced a global license agreement with Alchemedicine to strengthen its drug discovery pipeline.  The agreement means Asahi Kasei Pharma can research, develop, manufacture, and commercialise Alchemedicine’s novel lead compounds, which are currently at the preclinical stage.  The compounds were identified using Alchemedicine’s drug discovery platform, HiSAP1 and are expected to have therapeutic potential for multiple autoimmune diseases. The specific target […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!